Alnylam Pharmaceuticals

Últimas notícias

Manchetes no idioma original da fonte.

• Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49% (abre em uma nova aba)

  Simply Wall Street · 2 de out. de 2026

• Alnylam Pharmaceuticals, Carvana, MongoDB (abre em uma nova aba)

  TradingView · 30 de set. de 2026

• Alnylam drafts football veteran Pete Shaw for heart disease education push (abre em uma nova aba)

  Fierce Pharma · 30 de set. de 2026

• Down 35% This Year, Alnylam Still Has Wall Street Calling 44% Upside (abre em uma nova aba)

  NAI500 · 29 de set. de 2026

• Alnylam shares drop 18% after AstraZeneca/Ionis trial failure, but outlook remains cautiously optimistic. (abre em uma nova aba)

  Pluang · 28 de set. de 2026

• Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY) (abre em uma nova aba)

  Seeking Alpha · 28 de set. de 2026

• 18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. (abre em uma nova aba)

  The Motley Fool · 28 de set. de 2026

• Form 4 Alnylam Pharmaceuticals Inc For: 27 September By Investing.com (abre em uma nova aba)

  Investing.com Nigeria · 27 de set. de 2026

• Alnylam Needs Stronger AMVUTTRA Execution To Justify More Upside (NASDAQ:ALNY) (abre em uma nova aba)

  Seeking Alpha · 26 de set. de 2026

• The next Alnylam? RNAi biotech City Therapeutics files for IPO (abre em uma nova aba)

  Endpoints News · 25 de set. de 2026

• Alnylam Pharmaceuticals (ALNY) Short Interest & Short Float | Updated Sep 2026 $ALNY (abre em uma nova aba)

  MarketBeat · 24 de set. de 2026

• H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $455 (abre em uma nova aba)

  Moomoo · 21 de set. de 2026

• Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook (abre em uma nova aba)

  Yahoo Finance · 20 de set. de 2026

• Will RNAi Market Growth Change Alnylam Stock's Narrative? (abre em uma nova aba)

  Simply Wall Street · 20 de set. de 2026

• Alnylam Pharmaceuticals (ALNY) Highlighted As An Oligonucleotide Therapeutics Leader Through 2035 (abre em uma nova aba)

  Simply Wall Street · 17 de set. de 2026

• Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture (abre em uma nova aba)

  The Motley Fool · 15 de set. de 2026

• Alnylam at Morgan Stanley conference: ttr growth offsets guidance trim (abre em uma nova aba)

  Investing.com · 14 de set. de 2026

• Alnylam Pharmaceuticals (ALNY) Slides 3.99% to $247.71 as Shares Retreat From Recent Highs - Gap Fill Strategy (abre em uma nova aba)

  dars.gov.et · 10 de set. de 2026

• Here’s Why Alnylam Pharmaceuticals (ALNY) Declined (abre em uma nova aba)

  Yahoo Finance · 10 de set. de 2026

• Alnylam Pharmaceuticals (ALNY) Slides 3.99% to $247.71 as Shares Retreat From Recent Highs - Safe Entry Stocks (abre em uma nova aba)

  dars.gov.et · 10 de set. de 2026

• Why Alnylam Pharmaceuticals (ALNY) Stock Is Down Today (abre em uma nova aba)

  Quiver Quantitative · 10 de set. de 2026

• Alnylam Pharmaceuticals (ALNY) Slides 3.99% to $247.71 as Shares Retreat From Recent Highs - Moving Average Crossovers (abre em uma nova aba)

  dars.gov.et · 10 de set. de 2026